News about <![CDATA[US29264F2056]]> News about en-us <![CDATA[Stocks Hitting 52-Week Lows]]> Endo Health Solutions (NASDAQ: ENDP) shares declined 3.73% to touch a new 52-week low of $25.27. Analysts at Piper Jaffray downgraded Endo Health from “overweight” to “neutral.”

Silvercorp Metals (NYSE: SVM) shares lost 2.86% to create a new 52-week low of $4.75. Silvercorp Metals' PEG ratio is

]]> <![CDATA[UPDATE: Piper Jaffray Downgrades Endo Health Solutions to Neutral, Lowers PT]]> In a report published Friday, Piper Jaffray & Co. downgraded its rating on Endo Health Solutions (NASDAQ: ENDP) from Overweight to Neutral, and lowered its price target from $37.00 to $28.00.

Piper Jaffray noted, “We are downgrading Endo to a Neutral from an Overweight and lowering our price target

]]> <![CDATA[UPDATE: JP Morgan Cuts PT to $35 on Endo Health Solutions Ahead of Guidance]]> JP Morgan reiterated its Overweight rating on Endo Health Solutions (NASDAQ: ENDP) and lowered its price target from $38 to $35.

JP Morgan commented, "With no clear recovery in Opana ER prescriptions and following Endo's recent guidance updates, we are reducing

]]> <![CDATA[Endo Health Solutions Offers Comment on Dismissal of Suit Against FDA]]> Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that U.S. District Judge Reggie B. Walton, of the U.S. District Court for the District of Columbia, dismissed the case of Endo's subsidiary, Endo Pharmaceuticals Inc., against the U.S. Food and Drug Administration (FDA).  Endo Pharmaceuticals argued that FDA failed to meet its legal obligation

]]> <![CDATA[Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Revenue]]> Below are the top mid-cap drug manufacturers-other stocks on the NYSE and the NASDAQ in terms of revenue.

The trailing-twelve-month revenue at Forest Laboratories (NYSE: FRX) is $3.82 billion. Forest Laboratories' ROE for the same period is 9.98%.

The trailing-twelve-month revenue at Endo Health Solutions (NASDAQ: ENDP) is

]]> <![CDATA[Benzinga's Top Pre-Market Losers]]> Rigel Pharmaceuticals (NASDAQ: RIGL) shares fell 30.96% to $5.82 in the pre-market trading. Rigel Pharmaceuticals' trailing-twelve-month ROE is -45.82%.

Endo Health Solutions (NASDAQ: ENDP) shares dropped 6.38% to $25.84 in pre-market trading. Endo cut its earnings view for 2012 and 2013.

Ciena (NASDAQ: CIEN)

]]> <![CDATA[UPDATE: Endo Health Solutions Announces CEO Transition Plan; Won't Hit FY12, FY13 Guidance]]> Endo Health Solutions Inc. (Nasdaq: ENDP) announced today David P. Holveck, 67, President and Chief Executive Officer, will retire in 2013.  He will continue to serve in his present positions until the earlier of his successor being in place or the May 2013 annual meeting of Endo shareholders.  Holveck will also leave

]]> <![CDATA[Endo Health Solutions Launches 7.5mg, 15mg Strengths of Reformulated, Crush-Resistant OPANA ER]]> Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that its subsidiary, Endo Pharmaceuticals Inc., has launched 7.5mg and 15mg strengths of its reformulated, designed to be crush-resistant, OPANA^® ER (oxymorphone HCl) product.  Now commercially available, the 7.5mg and 15mg options complete the launch of all approved strengths of the reformulated version of OPANA

]]> <![CDATA[UPDATE: Stifel Nicolaus Cuts PT to $40 on Endo Health Solutions on Competitive Headwinds]]> Stifel Nicolaus reiterated its Buy rating on Endo Health Solutions (NASDAQ: ENDP) but reduced its price target from $44 to $40.

Stifel Nicolaus noted, "Facing generic entry from Impax on its older, non tamper-resistant formulation (non-TRF) of Opana ER on 1/1/13, Endo had hoped to force a decision

]]> <![CDATA[Endo Health Solutions Confirms FDA Suit Related to Non-Tamper Resistant Oxymorphone]]>  Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that its subsidiary, Endo Pharmaceuticals Inc., has filed suit against the U.S. Food and Drug Administration (FDA) seeking a formal determination whether the original formulation of OPANA^® ER (oxymorphone HCl) was voluntarily removed from the market in 2012 for reasons of safety involving the misuse

]]> <![CDATA[Is Endo Pharmaceuticals Going to Seize Market Share?]]>